Krystal Biotech’s (KRYS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a report released on Monday morning, Benzinga reports. HC Wainwright currently has a $200.00 target price on the stock. HC Wainwright also issued estimates for Krystal Biotech’s Q3 2024 earnings at $1.02 EPS, Q4 2024 earnings at $2.06 EPS, FY2024 earnings at $4.01 EPS, FY2025 earnings at $6.91 EPS, FY2026 earnings at $6.47 EPS, FY2027 earnings at $8.61 EPS and FY2028 earnings at $8.73 EPS.

Separately, Stifel Nicolaus reaffirmed a buy rating and set a $204.00 price target (up from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Krystal Biotech currently has a consensus rating of Moderate Buy and an average price target of $185.63.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $180.37 on Monday. The firm’s 50 day moving average price is $186.25 and its 200-day moving average price is $164.61. Krystal Biotech has a 52-week low of $93.95 and a 52-week high of $219.34. The company has a market cap of $5.15 billion, a PE ratio of 96.45 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.03. The business had revenue of $70.28 million for the quarter, compared to the consensus estimate of $65.27 million. During the same quarter in the prior year, the business posted ($1.25) earnings per share. Krystal Biotech’s revenue for the quarter was up 70283900.0% on a year-over-year basis. On average, analysts forecast that Krystal Biotech will post 2 earnings per share for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, Director Julian S. Gangolli sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $164.13, for a total value of $3,282,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Krystal Biotech news, Director Julian S. Gangolli sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $164.13, for a total value of $3,282,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total value of $4,394,000.00. Following the completion of the transaction, the insider now directly owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in shares of Krystal Biotech by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock valued at $302,182,000 after buying an additional 35,632 shares in the last quarter. Jennison Associates LLC increased its position in shares of Krystal Biotech by 112.5% in the fourth quarter. Jennison Associates LLC now owns 724,344 shares of the company’s stock valued at $89,862,000 after buying an additional 383,495 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Krystal Biotech by 54.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock valued at $117,189,000 after buying an additional 231,255 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Krystal Biotech by 5.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 550,806 shares of the company’s stock valued at $68,337,000 after buying an additional 30,169 shares in the last quarter. Finally, Hood River Capital Management LLC increased its position in shares of Krystal Biotech by 8.1% in the first quarter. Hood River Capital Management LLC now owns 495,586 shares of the company’s stock valued at $88,180,000 after buying an additional 37,073 shares in the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).